Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by our licensees in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a proprietary product pipeline focused on treating diseases of the central nervous system and for the treatment of severe allergic reactions, including anaphylaxis.
We consult with and listen to our patients. Our technologies aim to address shortfalls in medication design that make it hard for patients to use the medicines they’re prescribed.
Our therapeutic solutions make life-saving medications available to those who need them most by enhancing the way they are delivered.
We are focused problem solvers who work to empower patients and their caregivers. Our team hails from a variety of backgrounds and disciplines, and has created a collaborative culture where different viewpoints are valued and challenging the status quo is the norm.
We’re fortunate to have experienced industry leaders on our active Board of Directors.
Our advisory board consists of world-renowned, experienced physicians who share our goal of simplifying complex treatment conditions to improve the patient experience in allergy.
